California State Teachers Retirement System lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 1.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,251 shares of the company’s stock after purchasing an additional 1,355 shares during the period. California State Teachers Retirement System owned approximately 0.09% of Vaxcyte worth $2,820,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. RA Capital Management L.P. lifted its stake in shares of Vaxcyte by 27.9% in the fourth quarter. RA Capital Management L.P. now owns 5,857,459 shares of the company’s stock valued at $280,865,000 after purchasing an additional 1,276,256 shares during the period. Vanguard Group Inc. lifted its stake in shares of Vaxcyte by 12.5% in the third quarter. Vanguard Group Inc. now owns 4,452,145 shares of the company’s stock valued at $106,851,000 after purchasing an additional 496,227 shares during the period. BlackRock Inc. lifted its stake in shares of Vaxcyte by 6.7% in the third quarter. BlackRock Inc. now owns 3,492,321 shares of the company’s stock valued at $83,817,000 after purchasing an additional 220,691 shares during the period. State Street Corp lifted its stake in shares of Vaxcyte by 7.4% in the third quarter. State Street Corp now owns 1,993,036 shares of the company’s stock valued at $47,833,000 after purchasing an additional 137,392 shares during the period. Finally, Carlyle Group Inc. purchased a new position in Vaxcyte during the 1st quarter valued at about $72,080,000. Institutional investors and hedge funds own 89.22% of the company’s stock.
Vaxcyte Price Performance
Shares of NASDAQ PCVX opened at $50.29 on Friday. The company has a market cap of $4.72 billion, a PE ratio of -14.97 and a beta of 0.90. Vaxcyte, Inc. has a 12 month low of $20.49 and a 12 month high of $54.97. The company has a 50-day simple moving average of $48.80 and a 200-day simple moving average of $45.73.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the stock. 888 restated a “reiterates” rating on shares of Vaxcyte in a report on Tuesday, May 9th. Needham & Company LLC restated a “buy” rating and set a $58.00 target price on shares of Vaxcyte in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $70.00 target price on shares of Vaxcyte in a report on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $65.00.
Vaxcyte Company Profile
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
- Five stocks we like better than Vaxcyte
- How to Invest in Music Stocks
- One of these 5 Pet Care Stocks Can Be the Next Short Squeeze
- What to Know About Investing in Penny Stocks
- 3 High Short Interest Stocks that Investors are Getting Wrong
- 3 Small Caps With Big Return Potential
- Retail Theft Rises: Two Ways For Investors To Beat Shrinkage
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.